March 30, 2012
Austin, Texas – Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas (“CPRIT”). CPRIT was established to expedite innovation and commercialization in the area of cancer research and [...]
March 30, 2012
The partnership enables CAMO Software’s Unscrambler® X multivariate analytical engines to be offered together with Optimal’s synTQ® Lite software, designed for PAT (Process Analytical Technology) environments in the life sciences industry. CAMO Software CEO, Paal Braathen, says, ”We are very pleased to be working more closely with Optimal, an established leader in process automation. Our [...]
NanoString Introduces Three New Products at AACR Annual Meeting
March 30, 2012
SEATTLE, Wash. – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter® Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill. NanoString’s suite [...]
March 30, 2012
DALLAS-- Food safety testing is now on wheels, and it’s coming to Dallas as part of a progressive North American tour to raise awareness about improving food safety. A state-of-the-art mobile laboratory that is run by AB SCIEX and Phenomenex, two scientific technology leaders, will be open for visitors at the Frito-Lay North America site [...]
Block MEMS Wins Contract to Participate in the Multi-Mission Multi-Threat Detection (M3TD) Program
March 30, 2012
Block MEMS has been awarded a contract by the Department of Defense's Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) to provide its LaserScan™ Analyzer for evaluation in the Multi-Mission Multi-Threat Detection (M3TD) Technology Evaluation program. The goal of the M3TD program is to evaluate currently available technology for chemical detection and the [...]
March 30, 2012
WALTHAM, Mass.– At the American Association for Cancer Research 2012 Annual Meeting (Booth #2306), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will be showcasing numerous solutions, posters and knowledge-sharing events in support of cancer-focused personalized medicine research. "PerkinElmer remains committed to [...]
Perten Headquarters Relocates to Larger Building
March 30, 2012
Perten Instruments headquarters in Stockholm, Sweden has moved to larger offices. Göran Sandén – Head of Global After-Market – states “We’ve added 11 new service, applications specialists, and engineers in the last two years. We were bursting at the seams in our old building. The new offices allow us to continue our growth in after-sales [...]
March 30, 2012
Austin, Texas – Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas (“CPRIT”). CPRIT was established to expedite innovation and commercialization in the area of cancer research and [...]
March 30, 2012
OMAHA, Neb.,– Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic’s NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina. The discussion, titled “Clinical [...]
March 30, 2012
SAN DIEGO, CA — Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced completion of an $11.8 million Series B financing. New investors Redmile Group and Claremont Creek Ventures and private investors from Genalyte’s Series A round participated in the Series B financing. Genalyte intends to use the new [...]
